Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2025 22:26 ET | Source: Daedalus Special Acquisition Corp.

Daedalus Special Acquisition Corp. Announces the Upsized Pricing of $225 Million Initial Public Offering

London, United Kingdom, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Daedalus Special Acquisition Corp. (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands...
December 08, 2025 20:31 ET | Source: Netcapital Inc.

Netcapital Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, announced today the grant of an inducement...
December 08, 2025 19:45 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven...
December 08, 2025 19:45 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus...
December 08, 2025 19:45 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60%...
December 08, 2025 18:30 ET | Source: Biogen Inc.

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List

TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
December 08, 2025 17:02 ET | Source: IREN

IREN Closes $2.3 Billion Convertible Notes Offering and the Repurchase of Existing Convertible Notes

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ: IREN) (“IREN”) today announced the closing of its offering of convertible senior notes and repurchase of certain existing...
December 08, 2025 17:00 ET | Source: Netcapital Inc.

Netcapital Inc. Announces Appointment of Rich Wheeless as CEO

NCPL to Expand Beyond Traditional Securities into Crypto and Blockchain-Enabled Investments BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a...
December 08, 2025 16:58 ET | Source: Nayax Ltd.

Nayax Announces Preliminary Results of Notes and Warrants Offering in Israel to Qualified Investors

HERZLIYA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX) (the “Company”) announced today, further to its announcement of December 7, 2025, that the Company completed...
December 08, 2025 16:30 ET | Source: Exicure, Inc.

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced...